SRNE
Sorrento Therapeutics Inc is a biotechnology company focused on the development of novel immunotherapies for oncology and autoimmune/inflammation diseases.
Sorrento Therapeutics, Inc. (SRNE) is rated C (2.2/5) on Deltasharpe Prism, scored against General sector peers. Its strongest pillar is Growth (B); its weakest is Momentum (D).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2022-09-30 | C+ (2.5) | B (3.4) | C+ (2.6) | D (1.3) | D (1.5) | C (2.2) |
| 2022-06-30 | C+ (2.5) | D- (1.1) | C+ (2.8) | D (1.2) | D (1.5) | D+ (1.8) |
| 2022-03-31 | C+ (2.5) | C+ (2.5) | B- (3.1) | D (1.3) | D (1.5) | C (2.2) |
| 2021-12-31 | C+ (2.5) | C- (1.9) | B- (3.1) | D (1.3) | D (1.5) | C- (2.1) |
| 2021-09-30 | C+ (2.5) | D+ (1.5) | B- (3.1) | D (1.3) | D (1.5) | C- (2.0) |